Trial results

Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial

NCT07734792 on ClinicalTrials.gov · last registry update 2026-10-01

An unusually large phase 2/phase 3: 726 participants, more than double the 60 typical for the stage. Due to report 31 May 2028, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: The primary efficacy outcome: Proportion of patients achieving an excellent functional outcome. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for cardiovascular disease, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

NOT_YET_RECRUITING

Phase

P2/P3

Drug

tirzepatide

Mounjaro, Zepbound

Sponsor

yifang zhu

Sponsor type

Other

Enrollment

726

Started

2026-09-20

Primary completion

2028-05-31 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

The primary efficacy outcome: Proportion of patients achieving an excellent functional outcome

Conditions studied

Acute Ischemic Stroke (AIS)

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.